Laennec (Human placenta hydrolyzate) in monotherapy of mixed etiology of steatohepatitis

Abstract

Liver regeneration is an important task in the treatment of any liver diseases. The key point is the restoration of the liver structure, regression of fibrosis and steatosis of the liver. Difficulties in the treatment of patients with steatohepatitis of metabolic and alcoholic etiology are associated with comorbidity and multicomponent drug load, problems of lifestyle modification. The use of a complex parenteral drug in the treatment of this group of patients increases patient compliance, minimizes the risks of drug interactions. The aim of the study: to evaluate the effect of course treatment with Laennec on insulin resistance, dyslipidemia, systemic inflammatory response, activity of inflammatory process in the liver, steatosis and liver fibrosis. Materials and methods. The study included 50 patients with steatohepatitis of mixed etiology with the presence of biochemical activity, obesity, dyslipidemia, insulin resistance, are having liver steatosis and liver fibrosis of at least stage 1 (determined by liver fibroscopy). 32 patients received Laennec 6 ml intravenously 3 times a week, then 6 ml intramuscularly once every 10 days up to 24 weeks, 18 patients took Omega 3 PUFAs orally 2000 mg per day for 24 weeks. Results. Significant differences (p<0.05) in the estimated parameters in the group of patients treated with Laennec: decreased activity of the inflammatory process-ALT-21% AST -24%, CRP -21%; GGTP cholestasis syndrome -26%; insulin resistance index -13%; correction of LDL dyslipidemia -17%, triglycerides -17%, CA -18%; liver steatosis- 20%. There was an 8% decrease in triglycerides (p<0,05) in the group receiving Omega 3 PUFAs. Conclusions. The use of Laennec in patients with steatohepatitis initiates a decrease in the activity of the inflammatory process in liver tissue, improves metabolic parameters and liver structure.